An observational study in Diabetes Mellitus, Glycemic Control and Cerebral Oxygenation, sponsored by Ege University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Ege University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 246 studies in Diabetes Mellitus with a site in Turkey — 37 open to participants now, 44 under way, 1 of them phase 3. Diabetes Mellitus · Turkey.
Among the 246 studies in Diabetes Mellitus with a site in Turkey, this one is the 70th largest by planned enrollment of the 97 observational ones that give a count, is one of 22 that started in 2025, is one of 97 observational ones, reaches primary completion later than 33 of the 43 other live ones, and was the 234th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →37 of the 246 studies in Diabetes Mellitus with a site in Turkey are open now. Recruiting first, the newest first:
Aylin DEMİR · Sites in Turkey
Ages 35–65
Bilecik Seyh Edebali Universitesi · Sites in Turkey
Ages 18–65
Abant Izzet Baysal University · Sites in Turkey
Ages 65+ · Healthy volunteers
Kırıkkale University · Sites in Turkey
Ages 30–75 · Men only · Healthy volunteers
Ataturk University · Sites in Turkey
Ages 50–80 · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
246 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 38 · Phase 4 15
First in 2002; this study’s year is marked. 22 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 246 across 1,935 observational studies indexed under Diabetes Mellitus.
Median enrollment 90 across the 147 interventional studies, 120 across the 97 observational. Of the 192 that completed or were terminated, 45 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
62 of 246 have an industry lead sponsor. The 10 most frequent:
Ege University is the lead sponsor of 377 studies on the registry; 48 are open to participants now.
Ege University has 3 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
8 of the studies in Diabetes Mellitus with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07491185Ege UniversityEffect of Glycemic Control on Intraoperative NIRS and Postoperative Recovery in Diabetic Patients | 2026-11 |
| NCT07444697Kırıkkale University"Erectile Function After PCI in MI and Non-MI Patients" | 2026-11 |
| NCT07734428Istanbul Bilgi UniversityInflammation and Diabetes: Evaluating Antioxidant Levels | 2026-12-30 |
| NCT07329985Bilecik Seyh Edebali UniversitesiFEAR of HYPOGLYCEMIA in PATIENTS WITH DIABETES | 2027-01-15 |
| NCT07905274Bandırma Onyedi Eylül UniversitySarcopenia Risk in Obese T2DM Patients | 2027-03-20 |
Add all 8 to your calendar (.ics) → With an account.
Among the 246 studies in Diabetes Mellitus with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective observational study aims to evaluate the effect of glycemic control level on intraoperative cerebral oxygenation measured by near-infrared spectroscopy (NIRS) and postoperative recovery in patients with diabetes mellitus undergoing elective urologic surgery under general anesthesia.
Patients will be grouped according to HbA1c levels to assess the relationship between long-term glycemic control and intraoperative regional cerebral oxygen saturation, hemodynamic parameters, and postoperative recovery scores.
Diabetes mellitus is associated with increased perioperative morbidity and mortality, particularly in patients with poor long-term glycemic control. Elevated HbA1c levels may impair microcirculation and tissue oxygenation, which can affect cerebral perfusion during general anesthesia. Near-infrared spectroscopy (NIRS) is a non-invasive monitoring technique that allows continuous measurement of regional cerebral oxygen saturation and may help detect intraoperative hypoperfusion.
This prospective observational study is designed to investigate the relationship between glycemic control level and intraoperative cerebral oxygenation as well as postoperative recovery parameters in patients undergoing elective urologic surgery under general anesthesia. Patients will be divided into four groups according to preoperative HbA1c levels, including non-diabetic patients and diabetic patients with different levels of glycemic control.
Intraoperative monitoring will include standard hemodynamic parameters and bilateral regional cerebral oxygen saturation measured with near-infrared spectroscopy. The primary objective of the study is to determine whether poor glycemic control is associated with impaired cerebral oxygenation during anesthesia. Secondary objectives include evaluation of postoperative recovery parameters in relation to glycemic control level.
Adult patients scheduled for elective urologic surgery under general anesthesia at a single tertiary university hospital will be included. The study population consists of patients with diabetes mellitus with different levels of glycemic control and non-diabetic control patients. Participants will be grouped according to preoperative HbA1c levels.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Non-diabetic patients
Diabetic patients with HbA1c between 6% and 7%
Diabetic patients with HbA1c between 7% and 8%
Diabetic patients with HbA1c greater than 8%
Change in Regional Cerebral Oxygen Saturation (rSO2)
Regional cerebral oxygen saturation measured intraoperatively using near-infrared spectroscopy and compared between groups according to HbA1c level.
Time frame: Intraoperative period (from anesthesia induction to extubation)
Plan to share: No — Individual participant data will not be shared due to institutional regulations and privacy restrictions.
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Nov 2026, 12 months after the start.
Of 534 non-industry observational studies under Diabetes Mellitus, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 159. This study's planned 12 months is below that.
Counting every sponsor, half of 643 studies reached it within 36 months; a quarter within 14 and three quarters within 122.
Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Nov 12, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.